MabThera’ s sikkerhedsprofil ved non- Hodgkin lymfom og kronisk lymfocytiks leukæmi er baseret på data fra patienter fra kliniske studier og fra post- marketing overvågning.
The overall safety profile of MabThera in non-Hodgkin’ s lymphoma and chronic lymphocytic leukaemia is based on data from patients from clinical trials and from post-marketing surveillance.